title: A role of phosphodiesterase-3B pathway in mediating leptin action on proopiomelanocortin and neurotensin neurons in the hypothalamus.
abstract: Leptin signaling in the hypothalamus is required for normal food intake and body weight homeostasis. Recent evidence suggests that besides the signal transducer and activator of transcription-3 (STAT3) pathway, several non-STAT3 pathways mediate leptin signaling in the hypothalamus. We have previously demonstrated that leptin stimulates phosphodiesterase-3B (PDE3B) activity in the hypothalamus, and PDE3 inhibitor cilostamide reverses anorectic and body weight reducing effects of leptin. To establish the physiological role of PDE3B signaling in the hypothalamus, we examined if leptin signaling through the PDE3B pathway is responsible for the activation of proopiomelanocortin (POMC) and neurotensin (NT) neurons, which are known to play a critical role in energy homeostasis. To this end, we assessed the effect of cilostamide on leptin-induced POMC and NT gene expression in the rat hypothalamus. Results showed that while central injection of leptin significantly increased both POMC and NT mRNA levels in the medial basal hypothalamus, cilostamide completely reversed this effect of leptin suggesting a PDE3B-activation dependent induction of POMC and NT gene expression by leptin. This result further suggests that the PDE3B pathway plays an important role in mediating leptin action in the hypothalamus.
authors.affiliation: Department of Cell Biology and Physiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. asahu@pitt.edu
authors.forename: Abhiram
authors.initials: A
authors.lastname: Sahu
mesh_terms: D000818:Animals; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3 / Q000378:metabolism*; D015870:Gene Expression; D007031:Hypothalamus / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D020738:Leptin / Q000378:metabolism*; D008297:Male; D008959:Models, Neurological; D009474:Neurons / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D009496:Neurotensin / Q000235:genetics / Q000378:metabolism*; D058987:Phosphodiesterase 3 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D011333:Pro-Opiomelanocortin / Q000235:genetics / Q000378:metabolism*; D015363:Quinolones / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D015398:Signal Transduction
chemical_list: D020738:Leptin; D058987:Phosphodiesterase 3 Inhibitors; D010726:Phosphodiesterase Inhibitors; D015363:Quinolones; D012333:RNA, Messenger; D009496:Neurotensin; C021294:cilostamide; D011333:Pro-Opiomelanocortin; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; C517294:Pde3b protein, rat
references.citation: Cell Metab. 2009 Nov;10(5):343-54
references.pmid: 19883613
references.citation: Eur J Pharmacol. 1982 Jul 16;81(3):499-503
references.pmid: 6811292
references.citation: Peptides. 1987 Sep-Oct;8(5):921-6
references.pmid: 2448757
references.citation: Neuron. 2004 Jun 24;42(6):983-91
references.pmid: 15207242
references.citation: J Clin Invest. 2008 May;118(5):1796-805
references.pmid: 18382766
references.citation: Nature. 2000 Apr 6;404(6778):661-71
references.pmid: 10766253
references.citation: Mol Endocrinol. 2008 Mar;22(3):751-9
references.pmid: 18096691
references.citation: Nat Genet. 1996 Sep;14(1):95-7
references.pmid: 8782827
references.citation: J Biol Chem. 2000 May 12;275(19):14563-72
references.pmid: 10799542
references.citation: Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):16064-9
references.pmid: 15520383
references.citation: Endocrinology. 2003 Sep;144(9):3789-98
references.pmid: 12933650
references.citation: Endocrinology. 2007 Jan;148(1):72-80
references.pmid: 17023536
references.citation: J Biol Chem. 1997 Mar 7;272(10):6093-6
references.pmid: 9102398
references.citation: Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8878-83
references.pmid: 9238071
references.citation: J Biol Chem. 1988 Apr 5;263(10):4963-8
references.pmid: 2832414
references.citation: Endocrinology. 1980 Jul;107(1):47-54
references.pmid: 6991249
references.citation: J Comp Neurol. 1998 Jun 15;395(4):535-47
references.pmid: 9619505
references.citation: Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4661-6
references.pmid: 15070774
references.citation: J Neurosci. 2001 Apr 1;21(7):2413-24
references.pmid: 11264315
references.citation: Diabetes. 2001 Feb;50(2):425-35
references.pmid: 11272157
references.citation: Endocrinology. 2003 May;144(5):2121-31
references.pmid: 12697721
references.citation: J Biol Chem. 1997 Dec 19;272(51):32686-95
references.pmid: 9405487
references.citation: Neurosci Lett. 2008 Aug 1;440(2):125-9
references.pmid: 18562101
references.citation: Nature. 2003 Feb 20;421(6925):856-9
references.pmid: 12594516
references.citation: Pharmacol Biochem Behav. 1983 Jan;18(1):19-23
references.pmid: 6131439
references.citation: J Neuroendocrinol. 2005 Nov;17(11):720-6
references.pmid: 16219000
references.citation: Nature. 2004 Apr 1;428(6982):569-74
references.pmid: 15058305
references.citation: Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8374-8
references.pmid: 8710878
references.citation: Trends Endocrinol Metab. 1999 Aug;10(6):211-216
references.pmid: 10407394
references.citation: J Neuroendocrinol. 1992 Feb;4(1):79-89
references.pmid: 21554581
references.citation: Nature. 1998 Oct 22;395(6704):763-70
references.pmid: 9796811
references.citation: Front Neuroendocrinol. 2003 Dec;24(4):225-53
references.pmid: 14726256
references.citation: Nature. 2001 Oct 25;413(6858):794-5
references.pmid: 11677594
references.citation: J Clin Invest. 2001 Oct;108(8):1113-21
references.pmid: 11602618
references.citation: Mol Endocrinol. 1997 Apr;11(4):393-9
references.pmid: 9092791
references.citation: Cell Metab. 2008 Apr;7(4):291-301
references.pmid: 18396135
references.citation: Brain Res. 2001 Jan 12;888(2):343-347
references.pmid: 11150496
references.citation: Am J Physiol Regul Integr Comp Physiol. 2004 Jan;286(1):R143-50
references.pmid: 12958061
references.citation: J Biol Chem. 2001 Feb 16;276(7):4747-55
references.pmid: 11085989
references.citation: Science. 2006 May 12;312(5775):927-30
references.pmid: 16690869
references.citation: Neuron. 1999 Aug;23(4):775-86
references.pmid: 10482243
references.citation: J Neuroendocrinol. 2002 Oct;14(10):796-804
references.pmid: 12372004
references.citation: Nature. 1994 Dec 1;372(6505):425-32
references.pmid: 7984236
references.citation: J Clin Endocrinol Metab. 1999 Feb;84(2):711-7
references.pmid: 10022442
references.citation: Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6231-5
references.pmid: 8692797
references.citation: Nat Med. 2006 May;12(5):534-40
references.pmid: 16604086
references.citation: Peptides. 2004 Dec;25(12):2135-8
references.pmid: 15572202
references.citation: J Neurosci. 2005 Oct 12;25(41):9497-506
references.pmid: 16221860
references.citation: Nat Neurosci. 2002 Aug;5(8):727-8
references.pmid: 12101402
references.citation: J Clin Invest. 2000 Jun;105(12):1827-32
references.pmid: 10862798
references.citation: Endocrinology. 1998 Feb;139(2):795-8
references.pmid: 9449656
references.citation: Methods Mol Biol. 2000;153:219-30
references.pmid: 10957996
references.citation: Peptides. 1983 Jul-Aug;4(4):493-500
references.pmid: 6685868